Innospera Pharma Appoints Dr. Glenn Crater as Chief Medical Officer to Support Advancement of ING-006 Toward the Clinic
Article content
MONTREAL — Innospera Pharma Inc. ('Innospera'), a private, near-clinical-stage biotechnology company advancing differentiated small molecule modulators of GPR84 and GPR40 to treat inflammatory and metabolic diseases, today announced the appointment of Dr. Glenn Crater, MD, FCCP as Chief Medical Officer (CMO). Glenn will start immediately as a fractional CMO, with the commitment to joining full time as the Company's lead compound reaches the clinic.
Article content
Dr. Crater brings to Innospera over 25 years of clinical, regulatory, and leadership experience in pulmonary medicine and drug development. A board-certified pulmonologist, Dr. Crater has played pivotal roles in advancing respiratory drug candidates, with particular expertise in Idiopathic Pulmonary Fibrosis (IPF) — the initial target indication for Innospera's lead compound, ING-006, which is poised to enter clinical development in the near future.
Article content
'We are thrilled to welcome Glenn to Innospera at this critical moment in our growth,' said François Ravenelle, PhD, Chief Executive Officer of Innospera. 'Having worked closely with Glenn at Inversago Pharma, I've witnessed first-hand his commitment to scientific rigor, clinical excellence, and patient impact. His deep understanding of IPF and drug development will be invaluable as we initiate clinical studies for ING-006 and build a pipeline of novel GPR84/GPR40 modulators.'
Article content
Prior to joining Innospera, Dr. Crater served as Chief Medical Officer at multiple biotechnology companies and held senior medical leadership positions across both private and public firms, contributing to successful regulatory submissions and clinical programs in respiratory and fibrotic diseases.
Article content
'I'm excited to reunite with François and the team at Innospera,' said Dr. Crater. 'ING-006 represents a promising new approach to modulating inflammation and fibrosis via GPCR lipid signaling. I look forward to advancing this program in the clinic and working to deliver transformative therapies for patients living with IPF and related diseases.'
Article content
About Innospera Pharma
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants
Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV in newborns and infants born during or entering their first RSV season. The drug will be marketed under the brand name Enflonsia. The FDA's decision came a day ahead of the previously announced target date of June 10, 2025. The approval is based on data from the pivotal phase IIb/III CLEVER study, which showed that treatment with a single dose of Enflonsia significantly reduced the incidence of RSV disease and hospitalization in healthy preterm and full-term infants. Merck plans to launch Enflonsia in the United States ahead of the upcoming 2025-26 RSV season and expects ordering for the shots to start next month. Per a Reuters article, Merck will price the antibody at $556 per dose. Merck's Stock Performance Year to date, Merck's shares have lost 20% compared with the industry 's 1% decline. Other RSV Antibodies/Vaccines Available in the Market Once commercially launched, Merck's Enflonsia will face stiff competition from AstraZeneca AZN / Sanofi 's SNY RSV antibody Beyfortus, which was also approved for a similar indication in 2023. This AstraZeneca-Sanofi antibody achieved blockbuster status in its first full-year sales in 2024. Coincidentally, on the same day Enflonsia received approval, Sanofi revealed an aggressive effort to increase the supply of the AstraZeneca-partnered Beyfortus, including a plan to start shipping the antibody early in the third quarter of 2025. While there are multiple vaccines approved for preventing RSV in the United States, the only one approved for immunizing infants is Pfizer 's PFE Abrysvo. Unlike Beyfortus and Enflonsia, which can be administered directly, the Pfizer vaccine protects infants through maternal immunization. Most of the marketed RSV vaccines, including Pfizer's, are approved for use in older adults aged 60 years and above. MRK's Cholesterol Drug Meets Goal in Two Late-Stage Studies In a separate press release, Merck announced topline data from two phase III studies, CORALreef HeFH and CORALreef AddOn, which evaluated their investigational oral PCSK9 inhibitor, enlicitide decanoate, in adults with hyperlipidemia who had been previously treated with a statin. Both studies met their primary and key secondary endpoints, showing statistically significant and clinically meaningful greater reductions in low-density lipoprotein cholesterol (LDL-C) after treatment with enlicitide. While the CORALreef HeFH evaluated the drug against a placebo, the CORALreef AddOn assessed the drug against other oral non-statin therapies. MRK's Zacks Rank Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report This article originally published on Zacks Investment Research (
National Post
27 minutes ago
- National Post
EDETEK Engages Capgemini to Support Its Global Transformation Initiative and Accelerate AI Innovation in Clinical Development
Article content NEW YORK — EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advancements in digital transformation within the life sciences industry. This engagement combines EDETEK's deep domain expertise and established platforms and services with Capgemini's advanced AI and engineering capabilities, to enable EDETEK to deliver innovative solutions aimed at optimizing clinical development, improving operational efficiency, and accelerating the time-to-market for new therapies. Article content A shared vision for the future of clinical R&D Article content Article content By integrating advanced digital and data capabilities—including generative AI—across all phases of clinical trials, the project will support new efficiencies for pharmaceutical companies, including: Article content Dramatically reduce time-to-market for new therapies. Enablement of self-learning, insight-driven trials for faster, more proactive decision-making. Streamlined data management and trial workflows, enhancing efficiency and precision. Significant cost reductions and boosted drug pipeline value. Article content 'Working with Capgemini signifies our continuing efforts to expand our global capabilities towards delivering more effective and faster clinical development,' Article content said Dr. Shakthi Kumar, Chief Strategy & Business Officer at EDETEK. Article content 'By bringing together our AI-driven platforms with Capgemini's leading capabilities in life science and technology, we will empower life science organizations to conduct smarter, faster, and more predictive clinical trials—ultimately improving patient outcomes at scale.' Article content Bringing innovation to clinical development at scale Article content The engagement combines EDETEK's proven technology with Capgemini's global network and deep domain knowledge to scale AI-powered clinical innovation across the pharmaceutical industry. Together, this will help make intelligent, agile, and data-driven clinical trials accessible to more life sciences organizations worldwide. In addition, Capgemini will leverage its robust engineering capabilities to help scale EDETEK's platforms globally and enable continued leadership in reliability, innovation, and performance. Article content 'Our deep expertise in next-gen clinical development methodologies and advanced AI will expand EDETEK's R&D cloud and eClinical platform, helping its clients to unlock new levels of agility, insight, and efficiency,' Article content said Thorsten Rall, Global Industry Head, Life Sciences at Capgemini. 'Together, we are committed to redefining what's possible for the industry—delivering measurable value, accelerating innovation, and shaping the future of healthcare through smarter, more predictive clinical trials.' Article content About EDETEK, Inc. Article content Founded in 2009, EDETEK delivers high-quality AI-powered platforms and clinical services to over one hundred biopharma clients worldwide. With a presence across four continents, EDETEK is redefining the future of clinical development through intelligent technology. Article content For more information about EDETEK, please visit About Capgemini Capgemini is a global business and technology transformation partner, helping organizations to accelerate their dual transition to a digital and sustainable world, while creating tangible impact for enterprises and society. It is a responsible and diverse group of 340,000 team members in more than 50 countries. With its strong over 55-year heritage, Capgemini is trusted by its clients to unlock the value of technology to address the entire breadth of their business needs. It delivers end-to-end services and solutions leveraging strengths from strategy and design to engineering, all fueled by its market leading capabilities in AI, generative AI, cloud and data, combined with its deep industry expertise and partner ecosystem. The Group reported 2024 global revenues of €22.1 billion. Article content Article content Article content Contacts Article content Capgemini press contact: Article content Article content Julia Zimmerman Article content Article content Tel.:+1 847-922-7951 Article content Article content EDETEK press contact: Article content Article content Wei Kong Article content Article content Article content Article content
CBC
an hour ago
- CBC
Smoke blankets Alberta as fight against western wildfires continues
Social Sharing Smoke from wildfires burning across Alberta has blanketed much of the province, including the Edmonton region. Edmontonians woke up to worsening air quality — the distinct smell of burning wood and morning skies cloaked in an orange haze. Environment Canada has issued special air quality statements for the city and surrounding regions, while air quality warnings remain in effect for a swath of communities across the northern portion of the province. Air quality and visibility due to wildfire smoke could fluctuate from hour to hour and as smoke levels increase, so do the health risks, Environment Canada cautioned. As of Tuesday morning, the Air Quality Health Index for the Edmonton region was rated at 10+, meaning that residents are at a very high risk from the current levels of air pollution. Environment Canada is urging people to limit their time outside and to monitor themselves for symptoms of prolonged exposure, including difficulty breathing, wheezing, chest pains or severe cough. Environment Canada meteorologist Steven Flisfeder said that from B.C. to Quebec, Canadians could likely see and smell wildfire smoke. "We're seeing smoke present almost everywhere," Flisfeder said. "When we look at satellite imagery, we can see the presence of smoke stemming from these wildfires making their way across the Atlantic toward the U.K. and parts of Europe." He said the haze isn't dangerous when it remains in the Earth's upper atmosphere but when it descends, it becomes a health risk. Flisfeder added that winds are expected to shift in the coming days. A scorching season Smoke is drifting in from the northwest from fires burning in northern Alberta as well as northeastern B.C. Western Canada has faced a volatile start to wildfire season with explosive fire conditions and expanding evacuation orders straining emergency resources across the west. Between 10,000 and 15,000 remain under evacuation in Saskatchewan and another 21,000 have been forced from their homes in Manitoba, one of the largest evacuations in the province's history. Close to 3,000 Albertans remain on evacuation orders. On the front lines of the wildfire fight 6 hours ago Duration 2:45 A helicopter pilot, heavy machinery operator and railway worker talk about what they're doing on the front lines of the battle against wildfires in Manitoba. As of Tuesday morning, 65 wildfires were raging across the province, 24 of which are burning out of control. Seven of the fires are considered an imminent threat to critical infrastructure or communities. Among them is a blaze along the Alberta-B.C. border, which has grown relentlessly for days, triggering a string of evacuation orders. The blaze, known as the Kiskatinaw River wildfire, continues to burn out of control since crossing the border into Alberta. The fire flared dangerously over the weekend, forcing an evacuation of Kelly Lake in northeast B.C., and destroying several structures within the remote community. Aggressive fire behaviour Sunday afternoon prompted the County of Grande Prairie to issue an expanded evacuation order and alert. The fire grew significantly overnight Sunday, in what wildfire officials described as a stern warning about the continued risk to surrounding communities. The fire grew rapidly Monday and now covers 21,679 hectares. Drier fuels and poor overnight humidity recovery are expected to fuel the fire, especially in exposed areas and spruce stands. The wildfire continues to progress toward containment lines along the north side, officials said. Red Earth East Complex A complex of fires, known as the Red Earth East Complex, continues to threaten a cluster of remote northern Alberta communities. Residents of Peerless Lake, Trout Lake, Red Earth Creek and Loon River First Nation remain under evacuation, while around 100 residents of nearby Chipewyan Lake are assessing their losses after nearly half of the structures in the community burned. A wall of flames moved in on the community two weeks ago, temporarily trapping a firefighting crew on scene overnight as homes along with the community's health centre, church and water treatment plant were incinerated by the flames. The Sousa Creek fire forced residents of Chateh to flee last week. It's unclear when it will be safe to return to the town about 850 kilometres north of Edmonton. The fire remains five kilometres south of of Chateh and 72 kilometres west of the Town of High Level. It has now consumed more than 41,200 hectares of forest. Crews battling the fire have faced high winds and parched conditions which have threatened to push the fire toward the community. Firefighters and heavy equipment crews have been working to contain the fire along the north and northeastern perimeter near Sousa Creek. Shifting winds and soft wet soil deep in the bush has hampered those efforts, officials said. A smattering of rain showers were expected to fall on northern Alberta Monday but after weeks of hot, dry weather, conditions remain parched. Officials caution that the fire danger remains extreme, meaning the risk of fast-growing, volatile fires across the Alberta landscape remains dangerously high.
